FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807398426> ?p ?o ?g. }

• W2807398426 abstract "Abstract Background Osteosarcoma (OS) is a rare, malignant bone tumor that primarily affects adolescents and has a high degree of malignancy and high incidence of recurrence and metastasis. Our study aimed to explore the role of miR-338-3p in OS cells. Methods qRT-qPCR was performed to quantify miR-338-3p expression levels in OS tissue samples and in three common OS cell lines. MG-63 and Saos2 cells were separately transfected with miR-338-3p or NC mimics and miR-338-3p expression levels was determined by qRT-PCR. Cell proliferation was monitored using the Cell Counting Kit-8. Flow cytometer analysis was carried out to determine the distribution of cell cycle stages and apoptosis. Transwell assay was performed to measure the migratory and invasive capacities of MG-63 and Saos2 cells. The expression of Vimentin and E-cadherin was detected by western blot. Luciferase reporter assay, qRT-PCR and western blotting were performed to confirm the target of miR-338-3p. Results Analysis by qRT-PCR revealed that miR-338-3p was downregulated in the tissue samples of 20 OS patients when compared with that in their matched adjacent non-tumor tissues. Furthermore, miR-338-3p was significantly downregulated in three common OS cell lines, namely, MG-63, Saos2, and HOS, when compared with that in the human osteoblast cell line hFOB1.19. Analysis by luciferase reporter assay, qRT-PCR, and western blotting revealed that activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1) is a direct target of miR-338-3p. miR-338-3p overexpression led to significant reduction in AHSA1 protein levels in MG63 and Saos2 cells. miR-338-3p overexpression reduced cell viability and migration and invasion behavior of MG63 and Saos2 cells. In addition, miR-338-3p overexpression suppressed epithelial–mesenchymal transition (EMT), induced a significant G1-phase arrest and did not affect the apoptosis in both MG-63 and Saos2 cells. Moreover, overexpression of AHSA1 reversed the inhibitory effect of miR-338-3p overexpression on proliferation, cell cycle, apoptosis, EMT, migration, and invasion of MG63 and Saos2 cells, thereby suggesting that miR-338-3p acts as a tumor suppressor in OS cells by targeting AHSA1. Conclusions miR-338-3p/AHSA1 can serve as a potential therapeutic target for OS therapy." @default.
• W2807398426 created "2018-06-13" @default.
• W2807398426 creator A5000246340 @default.
• W2807398426 creator A5005268431 @default.
• W2807398426 creator A5041382481 @default.
• W2807398426 creator A5061914497 @default.
• W2807398426 creator A5064347076 @default.
• W2807398426 creator A5070011429 @default.
• W2807398426 creator A5081626215 @default.
• W2807398426 date "2018-04-02" @default.
• W2807398426 modified "2023-10-01" @default.
• W2807398426 title "microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1" @default.
• W2807398426 cites W144423133 @default.
• W2807398426 cites W1814922229 @default.
• W2807398426 cites W1990515594 @default.
• W2807398426 cites W2000217892 @default.
• W2807398426 cites W2014946489 @default.
• W2807398426 cites W2020448394 @default.
• W2807398426 cites W2046730500 @default.
• W2807398426 cites W2107277218 @default.
• W2807398426 cites W2124756133 @default.
• W2807398426 cites W2134684600 @default.
• W2807398426 cites W2140396463 @default.
• W2807398426 cites W2148268378 @default.
• W2807398426 cites W2150395328 @default.
• W2807398426 cites W2209519104 @default.
• W2807398426 cites W2403305259 @default.
• W2807398426 cites W2414314244 @default.
• W2807398426 cites W2518544521 @default.
• W2807398426 cites W2559471688 @default.
• W2807398426 cites W2583175391 @default.
• W2807398426 cites W2587242538 @default.
• W2807398426 cites W4249201955 @default.
• W2807398426 cites W3148267794 @default.
• W2807398426 doi "https://doi.org/10.1186/s12935-018-0551-x" @default.
• W2807398426 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8547048" @default.
• W2807398426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34702261" @default.
• W2807398426 hasPublicationYear "2018" @default.
• W2807398426 type Work @default.
• W2807398426 sameAs 2807398426 @default.
• W2807398426 citedByCount "35" @default.
• W2807398426 countsByYear W28073984262018 @default.
• W2807398426 countsByYear W28073984262019 @default.
• W2807398426 countsByYear W28073984262020 @default.
• W2807398426 countsByYear W28073984262021 @default.
• W2807398426 countsByYear W28073984262022 @default.
• W2807398426 countsByYear W28073984262023 @default.
• W2807398426 crossrefType "journal-article" @default.
• W2807398426 hasAuthorship W2807398426A5000246340 @default.
• W2807398426 hasAuthorship W2807398426A5005268431 @default.
• W2807398426 hasAuthorship W2807398426A5041382481 @default.
• W2807398426 hasAuthorship W2807398426A5061914497 @default.
• W2807398426 hasAuthorship W2807398426A5064347076 @default.
• W2807398426 hasAuthorship W2807398426A5070011429 @default.
• W2807398426 hasAuthorship W2807398426A5081626215 @default.
• W2807398426 hasBestOaLocation W28073984261 @default.
• W2807398426 hasConcept C104317684 @default.
• W2807398426 hasConcept C111335760 @default.
• W2807398426 hasConcept C145059251 @default.
• W2807398426 hasConcept C147447768 @default.
• W2807398426 hasConcept C153911025 @default.
• W2807398426 hasConcept C185592680 @default.
• W2807398426 hasConcept C203014093 @default.
• W2807398426 hasConcept C204232928 @default.
• W2807398426 hasConcept C2776415932 @default.
• W2807398426 hasConcept C2777760704 @default.
• W2807398426 hasConcept C502942594 @default.
• W2807398426 hasConcept C54009773 @default.
• W2807398426 hasConcept C54355233 @default.
• W2807398426 hasConcept C553184892 @default.
• W2807398426 hasConcept C55493867 @default.
• W2807398426 hasConcept C62112901 @default.
• W2807398426 hasConcept C81885089 @default.
• W2807398426 hasConcept C85265743 @default.
• W2807398426 hasConcept C86803240 @default.
• W2807398426 hasConceptScore W2807398426C104317684 @default.
• W2807398426 hasConceptScore W2807398426C111335760 @default.
• W2807398426 hasConceptScore W2807398426C145059251 @default.
• W2807398426 hasConceptScore W2807398426C147447768 @default.
• W2807398426 hasConceptScore W2807398426C153911025 @default.
• W2807398426 hasConceptScore W2807398426C185592680 @default.
• W2807398426 hasConceptScore W2807398426C203014093 @default.
• W2807398426 hasConceptScore W2807398426C204232928 @default.
• W2807398426 hasConceptScore W2807398426C2776415932 @default.
• W2807398426 hasConceptScore W2807398426C2777760704 @default.
• W2807398426 hasConceptScore W2807398426C502942594 @default.
• W2807398426 hasConceptScore W2807398426C54009773 @default.
• W2807398426 hasConceptScore W2807398426C54355233 @default.
• W2807398426 hasConceptScore W2807398426C553184892 @default.
• W2807398426 hasConceptScore W2807398426C55493867 @default.
• W2807398426 hasConceptScore W2807398426C62112901 @default.
• W2807398426 hasConceptScore W2807398426C81885089 @default.
• W2807398426 hasConceptScore W2807398426C85265743 @default.
• W2807398426 hasConceptScore W2807398426C86803240 @default.
• W2807398426 hasIssue "1" @default.
• W2807398426 hasLocation W28073984261 @default.
• W2807398426 hasLocation W28073984262 @default.
• W2807398426 hasLocation W28073984263 @default.
• W2807398426 hasLocation W28073984264 @default.
• W2807398426 hasOpenAccess W2807398426 @default.

• next